Table 4 Cardiovascular adverse events following TIL therapy

From: Cardiovascular complications of cellular immunotherapies and associated risk factors

Study

Population

Sample size

Heart failure (%)

Arrhythmia, N (%)

ACS/MI, N (%)

Myocarditis N(%)

Cardiac death N(%)

Fradley, et al.59

Melanoma

43

N/A

6 (14.0%)

1 (2.3%)

N/A

N/A

Borgers, et al.60

Melanoma & NSCLC

120

1 (0.08%)

1 (0.08%)

1 (0.08%)

2 (0.16%)

N/A

  1. ACS acute coronary syndrome, MI myocardial infarction, NSCLC non-small cell lung cancer, TIL tumor-infiltrating lymphocyte.
Back to article page